Float Short %

6.03

Margin Of Safety %

Put/Call OI Ratio

1.04

EPS Next Q Diff

EPS Last/This Y

0.15

EPS This/Next Y

0.04

Price

7.78

Target Price

25.54

Analyst Recom

1.08

Performance Q

-33.84

Upside

-507.2%

Beta

0.94

Ticker: OCUL

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	OCUL	10.26	1.21	0.54	127390
2026-01-26	OCUL	10.9	1.22	2.44	145884
2026-01-27	OCUL	10.84	1.26	0.86	157290
2026-01-28	OCUL	10.27	1.22	0.72	159534
2026-01-29	OCUL	9.95	1.20	0.64	163006
2026-01-30	OCUL	9.13	1.19	0.68	164545
2026-02-02	OCUL	9.14	1.18	0.10	170851
2026-02-03	OCUL	8.51	1.11	0.27	179598
2026-02-05	OCUL	8.92	1.07	1.59	190033
2026-02-09	OCUL	9.43	0.97	1.35	198296
2026-02-10	OCUL	9.02	0.98	2.31	205194
2026-02-11	OCUL	9.16	1.07	2.33	226288
2026-02-12	OCUL	9.05	1.09	3.44	231585
2026-02-13	OCUL	8.88	1.17	2.05	241756
2026-02-17	OCUL	6.99	1.19	1.65	245078
2026-02-18	OCUL	6.88	1.14	0.24	244270
2026-02-19	OCUL	7.02	1.09	0.32	246884
2026-02-20	OCUL	7.79	1.04	0.55	243624
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	OCUL	10.28	-16.1	-	-1.43
2026-01-26	OCUL	10.91	-16.1	-	-1.43
2026-01-27	OCUL	10.84	-16.1	-	-1.43
2026-01-28	OCUL	10.30	-16.1	-	-1.43
2026-01-29	OCUL	9.95	-16.1	-	-1.43
2026-01-30	OCUL	9.14	-16.1	-	-1.43
2026-02-02	OCUL	9.14	-16.1	-	-1.43
2026-02-03	OCUL	8.52	-16.1	-	-1.43
2026-02-04	OCUL	8.56	-16.1	-	-1.43
2026-02-05	OCUL	8.92	-16.1	-	-1.43
2026-02-06	OCUL	9.17	-16.1	-	-1.43
2026-02-09	OCUL	9.44	-16.1	-	-1.43
2026-02-10	OCUL	9.03	18.1	-	-1.31
2026-02-11	OCUL	9.16	16.8	-	-1.30
2026-02-12	OCUL	9.04	16.8	-	-1.30
2026-02-13	OCUL	8.88	16.8	-	-1.30
2026-02-17	OCUL	6.99	16.8	-	-1.30
2026-02-18	OCUL	6.88	16.8	-	-1.30
2026-02-19	OCUL	7.03	19.4	-	-1.27
2026-02-20	OCUL	7.78	19.4	-	-1.27
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	OCUL	-0.43	19.45	6.63
2026-01-26	OCUL	-0.43	19.46	6.63
2026-01-27	OCUL	-0.43	19.46	6.63
2026-01-28	OCUL	-0.43	19.46	6.87
2026-01-29	OCUL	-0.43	19.46	6.87
2026-01-30	OCUL	-0.43	19.46	6.87
2026-02-02	OCUL	-0.43	19.50	6.87
2026-02-03	OCUL	-0.43	19.50	6.87
2026-02-04	OCUL	-0.43	19.50	6.87
2026-02-05	OCUL	-0.47	19.50	6.87
2026-02-06	OCUL	-0.47	19.50	6.87
2026-02-09	OCUL	-0.46	20.78	6.72
2026-02-10	OCUL	-0.46	20.78	6.72
2026-02-11	OCUL	-0.46	20.78	6.05
2026-02-12	OCUL	-0.46	20.78	6.05
2026-02-13	OCUL	-0.46	20.78	6.05
2026-02-17	OCUL	-0.46	24.51	6.04
2026-02-18	OCUL	-1.02	24.51	6.04
2026-02-19	OCUL	-1.02	24.51	6.04
2026-02-20	OCUL	-1.02	24.51	6.03
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

-0.31

Insider Transactions

-1.02

Institutional Transactions

24.51

Beta

0.94

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

63.8

Max Drawdown 5-Year %

-90

Target Price

25.54

P/E

Forward P/E

PEG

P/S

32.6

P/B

2.57

P/Free Cash Flow

EPS

-1.44

Average EPS Est. Cur. Y

-1.27

EPS Next Y. (Est.)

-1.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-511.9

Relative Volume

2.43

Return on Equity vs Sector %

-69.7

Return on Equity vs Industry %

-52.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.21

EBIT Estimation

Ocular Therapeutix, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 325

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today

news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance

stock history OCUL – Ocular Therapeutix, Inc. invest stock market

stock prices OCUL premarket after hours

ticker OCUL fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: OCUL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y